Andrea Bodor

Prof. Andrea Bodor

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2008 in Topics in Catalysis
Verified
Journal Article
Closed access
PDF file
HMHasan Mehdi
Hasan Mehdi
VFViktória Fábos
Viktória Fábos
RTRóbert Tuba
Róbert Tuba
ABAndrea Bodor
Andrea Bodor
LMLászló T. Mika
László T. Mika
IHIstvan Horvath
Istvan Horvath

29 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AHAnna Huber
Anna Huber
DHDorottya Hajdu
Dorottya Hajdu
DBDoris Bratschun-Khan
Doris Bratschun-Khan
ZGZoltán Gáspári
Zoltán Gáspári
MVMihayl Varbanov
Mihayl Varbanov
Gyula BattaGyula Batta
Gyula Batta
Small, cysteine-rich and cationic proteins with antimicrobial activity are produced by diverse organisms of all kingdoms and represent promising molecules for drug development. The ancestor of all industrial penicillin producing strains, the ascomycete Penicillium chryosgenum Q176, secretes the extensively studied antifungal protein PAF. However, the genome of this strain harbours at least two more genes that code for other small, cysteine-rich and cationic proteins with potential antifungal activity. In this study, we characterized the pafB gene product that shows high similarity to PgAFP from P. chrysogenum R42C. Although abundant and timely regulated pafB gene transcripts were detected, we could not identify PAFB in the culture broth of P. chrysogenum Q176. Therefore, we applied a P. chrysogenum-based expression system to produce sufficient amounts of recombinant PAFB to address unanswered questions concerning the structure and antimicrobial function. Nuclear magnetic resonance (NMR)-based analyses revealed a compact β-folded structure, comprising five β-strands connected by four solvent exposed and flexible loops and an “abcabc” disulphide bond pattern. We identified PAFB as an inhibitor of growth of human pathogenic moulds and yeasts. Furthermore, we document for the first time an anti-viral activity for two members of the small, cysteine-rich and cationic protein group from ascomycetes.

23 December 2006 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
HMHasan Mehdi
Hasan Mehdi
ABAndrea Bodor
Andrea Bodor
DLDiána Lantos
Diána Lantos
IHIstvan Horvath
Istvan Horvath
DVDirk E. De Vos
Dirk E. De Vos
KBKoen Binnemans
Koen Binnemans

19 May 2000 in Inorganic Chemistry
Verified
Journal Article
Closed access
ABAndrea Bodor
Andrea Bodor
ITI. Tóth
I. Tóth
IBI. Bányai
I. Bányai
ZSZ. Szabó
Z. Szabó
GHG. T. Hefter
G. T. Hefter

30 May 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MKMiklós Képiró
Miklós Képiró
BVBoglárka H. Várkuti
Boglárka H. Várkuti
ABAndrea Bodor
Andrea Bodor
GHGyörgy Hegyi
György Hegyi
LDLászló Drahos
László Drahos
AMAndrás Málnási-Csizmadia
András Málnási-Csizmadia
Photoreactive compounds are important tools in life sciences that allow precisely timed covalent crosslinking of ligands and targets. Using a unique technique we have synthesized azidoblebbistatin, which is a derivative of blebbistatin, the most widely used myosin inhibitor. Without UV irradiation azidoblebbistatin exhibits identical inhibitory properties to those of blebbistatin. Using UV irradiation, azidoblebbistatin can be covalently crosslinked to myosin, which greatly enhances its in vitro and in vivo effectiveness. Photo-crosslinking also eliminates limitations associated with the relatively low myosin affinity and water solubility of blebbistatin. The wavelength used for photo-crosslinking is not toxic for cells and tissues, which confers a great advantage in in vivo tests. Because the crosslink results in an irreversible association of the inhibitor to myosin and the irradiation eliminates the residual activity of unbound inhibitor molecules, azidoblebbistatin has a great potential to become a highly effective tool in both structural studies of actomyosin contractility and the investigation of cellular and physiological functions of myosin II. We used azidoblebbistatin to identify previously unknown low-affinity targets of the inhibitor (EC 50 ≥ 50 μM) in Dictyostelium discoideum , while the strongest interactant was found to be myosin II (EC 50 = 5 μM). Our results demonstrate that azidoblebbistatin, and potentially other azidated drugs, can become highly useful tools for the identification of strong- and weak-binding cellular targets and the determination of the apparent binding affinities in in vivo conditions.

1 January 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
GGGergő Gógl
Gergő Gógl
AAAnita Alexa
Anita Alexa
BKBence Kiss
Bence Kiss
GKGergely Katona
Gergely Katona
MKMihály Kovács
Mihály Kovács
LNLászló Nyitray
László Nyitray
Mitogen-activated protein kinases (MAPK) promote MAPK-activated protein kinase activation. In the MAPK pathway responsible for cell growth, ERK2 initiates the first phosphorylation event on RSK1, which is inhibited by Ca2+-binding S100 proteins in malignant melanomas. Here, we present a detailed in vitro biochemical and structural characterization of the S100B-RSK1 interaction. The Ca2+-dependent binding of S100B to the calcium/calmodulin-dependent protein kinase (CaMK)-type domain of RSK1 is reminiscent of the better known binding of calmodulin to CaMKII. Although S100B-RSK1 and the calmodulin-CAMKII system are clearly distinct functionally, they demonstrate how unrelated intracellular Ca2+-binding proteins could influence the activity of the CaMK domain-containing protein kinases. Our crystallographic, small angle x-ray scattering, and NMR analysis revealed that S100B forms a "fuzzy" complex with RSK1 peptide ligands. Based on fast-kinetics experiments, we conclude that the binding involves both conformation selection and induced fit steps. Knowledge of the structural basis of this interaction could facilitate therapeutic targeting of melanomas.